What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era?

Current Opinion in Ophthalmology

Volumn 26, Issue 3, 2015, Pages 177-183

  Agarwal, Aniruddha ^a   Sarwar, Salman ^a   Sepah, Yasir J ^a   Nguyen, Quan D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

antivascular endothelial growth factor; corticosteroids; diabetic macular edema; intravitreal injection; laser photocoagulation; neovascularization; vascular endothelial growth factor

Indexed keywords

CORTICOSTEROID; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CORTICOSTEROID THERAPY; COST OF ILLNESS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; EARLY INTERVENTION; HUMAN; PATIENT CARE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84926628113     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000152     Document Type: Review

References (66)

1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012; 366:1227-1239.
2. Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 2014; 132:1334-1340.
3. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105:998-1003.
4. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142:961-969.
5. Arevalo JF. Diabetic macular edema: changing treatment paradigms. Curr Opin Ophthalmol 2014; 25:502-507.
6. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064.e35-1077.e35.
7. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122:375-381
8. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117:1064.e35-1077.e35.
9. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122:375-381
10. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33:2399-2405.
11. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119:789-801.
12. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130:972-979.
13. Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009; 93:144-149.
14. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119:1658-1665.
15. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121:2247-2254.
16. Diabetic Retinopathy Clinical Research Network. Comparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for DME (Protocol T). 2014. Available at https://clinicaltrials.gov/ct2/show/ NCT01627249. [Accessed 29 January 2015]
17. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118:1580-1587.
18. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 121:1892-1903.
19. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119:1658-1665.
20. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121:2247-2254.
21. Diabetic Retinopathy Clinical Research Network. Comparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for DME (Protocol T). 2014. Available at https://clinicaltrials.gov/ct2/show/ NCT01627249. [Accessed 29 January 2015]
22. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118:1580-1587.
23. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 121:1892-1903.
24. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119:1658-1665.
25. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121:2247-2254.
26. Diabetic Retinopathy Clinical Research Network. Comparative effectiveness study of intravitreal aflibercept, bevacizumab, and ranibizumab for DME (Protocol T). 2014. Available at https://clinicaltrials.gov/ct2/show/ NCT01627249. [Accessed 29 January 2015]
27. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011; 118:1580-1587.
28. Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 121:1892-1903.
29. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121:1904-1914.
30. Bandello F, Preziosa C, Querques G, Lattanzio R. Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res 2014; 52:89-96.
31. Gonzalez VH, Boyer DS, Schmidt-Erfurth U, et al. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. Retina 2015. [Epub ahead of print]
32. Hatef E, Colantuoni E, Wang J, et al. The relationship between macular sensitivity and retinal thickness in eyes with diabetic macular edema. Am J Ophthalmol 2011; 152:400.e2-405.e2.
33. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012; 130:1145-1152.
34. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015; 122:367-374.
35. Domalpally A, Ip MS, Ehrlich JS. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology 2015; S0161-6420(14)01045-8. [Epub ahead of print]
36. Bressler SB, Qin H, Melia M, et al. Exploratory analysis of effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013; 131:1033-1040.
37. Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology 2013; 120:2004-2012.
38. Campochiaro PA, Wykoff CC, Shapiro H, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 2014; 121:1783-1789.
39. Genentech. FDA Grants breakthrough therapy designation to Lucentis for diabetic retinopathy. 2014. Available at http://one.aao.org/headline/fdagrants-breakthrough-therapy-designation-lucent. [Accessed 7 January 2015]
40. FDA Breakthrough Therapy Designation Chart. Available at https://orphandruganaut. wordpress.com/2013/05/20/fda-breakthrough-therapy-designationchart/. [Accessed 15 January 2015]
41. Regeneron Press Release. EYLEA (aflibercept) injection receives FDA breakthrough therapy designation for diabetic retinopathy in patients with diabetic macular edema. 2014. Available at http://investor.regeneron.com/release detail.cfm?ReleaseID=871009. [Accessed 15 January 2015]
42. Song SJ, Wong TY. Current concepts in diabetic retinopathy. Diabetes Metab J 2014; 38:416-425.
43. Fenwick EK, Pesudovs K, Rees G, et al. The impact of diabetic retinopathy: understanding the patient's perspective. Br J Ophthalmol 2011; 95:774-782.
44. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007; 27:816-824.
45. Virgili G, Parravano M, Menchini F, Evans JR. Antivascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 2014; 10:CD007419.
46. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121:2473-2481.
47. Alcubierre N, Rubinat E, Traveset A, et al. A prospective cross-sectional study on quality of life and treatment satisfaction in type 2 diabetic patients with retinopathy without other major late diabetic complications. Health Qual Life Outcomes 2014; 12:131.
48. Bressler NM, Varma R, Suner IJ, et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. Ophthalmology 2014; 121:2461-2472.
49. Lloyd AJ, Loftus J, Turner M, et al. Psychometric validation of the Visual Function Questionnaire-25 in patients with diabetic macular edema. Health Qual Life Outcomes 2013; 11:10.
50. Hariprasad SM, Mieler WF, Grassi M, et al. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 2008; 92:89-92.
51. Mitchell P, Bressler N, Tolley K, et al. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial. JAMA Ophthalmol 2013; 131:1339-1347.
52. Smiddy WE. Clinical applications of cost analysis of diabetic macular edema treatments. Ophthalmology 2012; 119:2558-2562.
53. Stein JD, Newman-Casey PA, Kim DD, et al. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology 2013; 120:1835-1842.
54. Pershing S, Enns EA, Matesic B, et al. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med 2014; 160:18-29.
55. Pruente C; RETAIN Study Group. Efficacy and safety of ranibizumab in two treat-and-extend versus pro-re-nata regimes in patients with visual impairment due to diabetic macular edema: 24-month results of RETAIN study. ARVO Meeting Abstracts 2014; 55:1700.
56. Cho H, Sobrin L. Genetics of diabetic retinopathy. Curr Diab Rep 2014; 14:515.
57. Agarwal A, Soliman MK, Sepah YJ, et al. Diabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomics. Pharmacogenomics Pers Med 2014; 7:399-409.
58. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116:1142-1150.
59. Shamsi HN, Masaud JS, Ghazi NG. Diabetic macular edema: new promising therapies. World J Diabetes 2013; 4:324-338.
60. A phase 1, open-label study of teprotumumab in patients with diabetic macular edema (DME). 2014. Available at https://clinicaltrials.gov/ct2/ show/NCT02103283. [Accessed 29 January 2015]
61. Campochiaro PA, Sophie R, Tolentino M, et al. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology 2015; 122:545-554.
62. Campochiaro PA, Channa R, Berger BB, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol 2013; 155:697-704; 704.e691-704.e692.
63. Inoue T, Morita M, Tojo T, et al. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment. Bioorg Med Chem 2013; 21:3873-3881.
64. Shen J, Frye M, Lee BL, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest 2014; 124:4564-4576.
65. Romero-Aroca P, Reyes-Torres J, Baget-Bernaldiz M, Blasco-Sune C. Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev 2014; 10:100-112.
66. Park YG, Kim EY, Roh YJ. Laser-based strategies to treat diabetic macular edema: history and new promising therapies. J Ophthalmol 2014; 2014: 769213.